<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184884</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0172</org_study_id>
    <nct_id>NCT02184884</nct_id>
  </id_info>
  <brief_title>Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength,
      maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in
      platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A
      study reported that the TEG® can be used as routine monitoring of the variability in ADP
      receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay,
      we could find out the perioperative clopidogrel responsiveness of the patients with ACS
      undergoing OPCAB.

      The purpose of this study is to determine whether the rate of the major adverse cardiac
      events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in
      the patients with high degree of clopidogrel resistance, who are scheduled to undergo the
      OPCAB due to ACS.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of the major adverse cardiac events</measure>
    <time_frame>at 30 days after surgery</time_frame>
    <description>major adverse cardiac events(MACE) includes the MI, revascularization and cardiac death. Rate of the MACE will be higher in the patients with high degree of clopidogrel resistance.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>MACE group</arm_group_label>
    <description>the patients with MACE after OPCAB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no MACE group</arm_group_label>
    <description>the patients without MACE after OPCAB</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MACE after OPCAB</intervention_name>
    <arm_group_label>MACE group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>without MACE after OPCAB</intervention_name>
    <arm_group_label>no MACE group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with acute coronary syndrome (ACS) undergoing off-pump coronary artery bypass
        surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. the patients with ACS undergoing OPCAB

          2. the patient administrate aspirin 100 mg and clopidogrel 75 mg at least 7 days and
             continue within 3days before surgery.

        Exclusion Criteria:

          1. re-operation or emergency operation

          2. the patients with bleeding tendency of decreased liver function

          3. Left ventricular ejection fraction &lt; 40% by echo

          4. preoperative hematocrit &lt; 33% or platelet count &lt; 100,000/mm3 or creatinine &gt; 1.4
             mg/dL

          5. abnormal preoperative prothrombin time or activated partial thromboplastin time

          6. preoperative use of other PO antiplatelet drugs or PO anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae-Kwang Shim, MD</last_name>
    <phone>82-10-5065-2733</phone>
    <email>aneshim@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Kwang Shim, MD</last_name>
      <phone>82-10-5065-2733</phone>
      <email>aneshim@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>off-pump coronary artery bypass surgery, clopidogrel responsiveness, ischemic outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

